DPIV

AcronymDefinition
DPIVDigital Particle Image Velocimetry
DPIVdipeptidyl-peptidase IV
References in periodicals archive ?
Using the DPIV video sequences, tentacles on one side of the medusa were digitized as series of points using ImageJ 1.
OSI's financial assets, which include significant DPIV patent royalties, substantial cash, investments and marketable securities, and net operating loss carryforwards of over $700 million as of December 31, 2009, are estimated to be worth approximately $1.
These more recent studies, however, do not provide the full-field velocity data of polymer melts that is possible with DPIV.
We are pleased to see the expanded use of this patent estate as new products in the significant emerging market for DPIV inhibitors are being brought forward," stated Anker Lundemose, M.
Glucose lowering effects and pharmacokinetics of 14-day treatment with the prandial DPIV inhibitor, PSN9301, in patients with type 2 diabetes - Rachman, Jonathan et al (Abstract # 546-P)
We believe that this license further validates the strength of our DPIV related patent estate and the importance of this target to the development of innovative new medicines for the treatment of diabetes," stated Anker Lundemose, M.
The development of inhibitors of DPIV (an enzyme catalyzing the breakdown of the natural hormone glucagon-like peptide-1 (GLP-1)) has become a very competitive area in the type 2 diabetes field.
OSI) Prosidion secured an additional non-exclusive license to its DPIV inhibitor patent estate.
PSN9301 is a novel oral DPIV inhibitor currently undergoing Phase II clinical trials where its efficacy and safety are being evaluated in type 2 diabetic patients.
NASDAQ: OSIP) announced today that its diabetes and obesity business unit, (OSI) Prosidion, has granted a worldwide non-exclusive license under its DPIV patent portfolio to a major Japanese pharmaceutical company.
6,890,898 and foreign equivalents thereof which claim combination therapy comprising administration of a DPIV inhibitor and another therapeutic agent for the treatment of type 2 diabetes and related indications.